Stereotactic Body Radiation Therapy (SBRT) for Select Pancreatic Cancer Patients (Part 2/2)
In short
SBRT delivers high doses of precisely targeted radiation over just five days, compared to the five to six weeks required for standard radiation — an approach that researchers are studying in pancreatic cancer patients whose tumors cannot be surgically removed, as well as those with borderline resectable disease. Radiation oncologist Dr. Joseph Herman explains how imaging advances, breathing-motion control, and tiny gold markers placed in the tumor allow doctors to treat with millimeter accuracy and lower toxicity. Early studies suggest some patients whose tumors were previously considered inoperable were able to have surgery after SBRT, and a few had no detectable tumor remaining at the time of surgery.
- •Ask your oncologist whether your tumor is locally advanced, borderline resectable, or involves blood vessels — these are the patients SBRT studies have focused on most.
- •If your tumor is near or growing into the stomach or intestines, ask your care team whether SBRT is appropriate for you, since those patients faced higher rates of serious side effects in one study.
- •SBRT's shorter five-day schedule may allow you to get back to full-dose chemotherapy sooner — ask your team how treatment sequencing could affect your overall plan.
- •SBRT is not a cure and is still being studied; ask your doctor whether a clinical trial combining SBRT with chemotherapy or immunotherapy might be an option for you.
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
potentially gives cancer more time to spread, he says. Quality of life is also an important factor. “Most patients we treat with SBRT have tumors that can’t be removed by surgery and that means average survival is only about one year,” Herman says. “These patients generally have to go through about six weeks of standard chemotherapy and radiation. That can be difficult for patients and their families. But with SBRT it’s only about five days.
That means patients spend a lot less time getting treatment and get to spend more time with family. ” Ongoing studies are testing combinations of SBRT with immunotherapy and researchers are also continuing to study the effectiveness of various radiation doses used in SBRT.
Looking To the Future Based on current data, Herman is hopeful that more studies will lead to SBRT becoming a standard-of-care option for patients with locally advanced or unresectable and borderline resectable pancreatic cancer with blood vessel involvement. Patients with involvement of the stomach or duodenum are not good candidates for SBRT, unless they are surgical candidates.
“There’s a lot of work to be done, and I want to stress this is not a cure,” Herman says. “We absolutely need randomized trials and we need to figure out the optimal dose and fractionation that will sterilize tumors for patients,” For example, researchers must still determine how best to combine SBRT with targeted or immunotherapeutic agents. Personalizing treatment based on factors like genetics and the tumor microenvironment are also goals.
“Pancreatic cancer patients need more options, and we need the trials to determine what their best options may be,” Herman states.
Highlights
from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.
Follow-up and Monitoring Managing Long-term Side Effects Emotional and Psychological Support Secondary Health Risks Lifestyle Changes As researchers search for ways to combat pancreatic cancer, one treatment gaining significant attention from the science community—and patients—is stereotactic body radiation therapy, or SBRT.
With traditional treatment, patients with early stage pancreatic tumors generally undergo surgery followed by chemotherapy, and sometimes radiotherapy as well. This conventional or standard radiation is delivered in relatively low doses, usually daily over the course of five to six weeks concurrently with chemotherapy.
An SBRT Primer But with SBRT, higher doses of carefully targeted radiation are used to treat tumors, delivered in a few “fractionated” doses. Sc. , a leading researcher in the use of SBRT in pancreatic cancer. Much of the credit for SBRT’s potential in treating pancreatic cancer has been due to technologic advances.
“Basically what’s happened is that radiation technology has improved and now we have very sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor,” he says. “That has allowed us to more precisely deliver radiation to tumors at much higher doses. ” Other improvements to the treatment include the control of a patient’s breathing motion since pancreatic tumors, like liver tumors, actually move during breathing.
Doctors have developed ways to control for this phenomenon by tracking a patient’s breathing motion or directly managing it. “Essentially what we do is have a patient inhale deeply, hold that breath, and then we freeze the tumor in space and treat it,” says Herman, formerly professor and director of clinical research at MD Anderson Cancer Center , Houston, Texas (now at Northwell Health, New York).
SBRT has also been aided through the use of fiducials—tiny gold markers—placed into the tumor that act as a kind of radiologic landmark, defining the target lesion's position with millimeter precision, he adds. Early Trials Answer Important Questions In a multi-institution study published in the journal Cancer , Dr. Herman and colleagues treated 49 patients with locally advanced pancreatic cancer with SBRT.
The patients received SBRT in five fractionated doses and chemotherapy with gemcitabine before and after the radiotherapy treatment. Four weeks after SBRT, all 22 patients who completed a quality of life questionnaire reported an eight point reduction in pain from a baseline measure of 25, and their quality of life stayed the same, which Herman says is encouraging.
In a second study, published in the Annals of Surgical Oncology , Herman and his colleagues analyzed information on patients with pancreatic cancer who received SBRT and chemotherapeutic drugs between 2010 and 2014. ) The study looked at acute and late toxicity of SBRT in locally advanced and borderline resectable pancreatic cancer. Of 88 patients, eight experienced severe gastrointestinal side effects.
Most of the patients who had side effects also had tumors that were invading into the intestines or stomach. For this reason, these patients should only get SBRT if the plan is to go to surgery following completion of SBRT. In this study, 19 patients with tumors previously considered inoperable (unresectable or locally advanced) were able to have surgery after SBRT.
Several patients had a complete response at the time of surgery, meaning there was no tumor left behind. To give people a surgical option is especially important since pancreatic tumors can often attach to and grow around blood vessels, making them difficult to remove, Herman says.
“But after SBRT, the tumor actually changes to a form that can be more easily pried away from the vessel,” he adds, citing the current published data with SBRT over five days provides at least equivalent or better outcomes in terms of survival, with less toxicity, and better pathologic response rates than what is generally seen with standard treatment over five to six weeks.
“In general, we don’t usually see this kind of response with standard radiation or chemotherapy alone,” he says. Another factor to consider is that shorter treatment times with SBRT may provide other benefits such as allowing patients access to full-dose chemotherapy much more quickly than those undergoing standard radiation which, because of its longer schedule, potentially gives cancer more time to spread, he says.
But with SBRT it’s only about five days.
Related pancreatic questions
- →Need recommendations for pancreatic cancer stage 4 that has spread to the liver. What treatment options are available
- →What are the must haves for someone soon to be receiving chemo by port for next 3 months, then followed by surgery?...
- →What is the real-world experience with daraxonrasib for metastatic pancreatic cancer, and how do patients tolerate it
- →What are the treatment options for Pancreatic Cancer
- →Which biomarker tests (KRAS, BRCA1/2) are recommended for my Pancreatic Cancer, and how will the results guide my...
- →What fertility preservation options exist before Pancreatic Cancer treatment in young adults
- →What is a multidisciplinary tumor board and should my Pancreatic Cancer case be presented
- →What is the 5-year survival rate for pancreatic cancer
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.